JP2007508011A - ヒトヒンジコアミメティボディ、組成物、方法および用途 - Google Patents

ヒトヒンジコアミメティボディ、組成物、方法および用途 Download PDF

Info

Publication number
JP2007508011A
JP2007508011A JP2006534031A JP2006534031A JP2007508011A JP 2007508011 A JP2007508011 A JP 2007508011A JP 2006534031 A JP2006534031 A JP 2006534031A JP 2006534031 A JP2006534031 A JP 2006534031A JP 2007508011 A JP2007508011 A JP 2007508011A
Authority
JP
Japan
Prior art keywords
hinge core
core mimetibody
hydrochloride
hinge
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508011A5 (enExample
Inventor
ヒーブナー，ジヨージ・エイ
ナイト，デイビツド・エム
スカロン，バーナード・ジエイ
グレイブ，ジヨン
ネスパー，トーマス・シー
フアング，シシ
Original Assignee
セントカー・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントカー・インコーポレーテツド filed Critical セントカー・インコーポレーテツド
Publication of JP2007508011A publication Critical patent/JP2007508011A/ja
Publication of JP2007508011A5 publication Critical patent/JP2007508011A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ceramic Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2006534031A 2003-09-30 2004-09-29 ヒトヒンジコアミメティボディ、組成物、方法および用途 Pending JP2007508011A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50723603P 2003-09-30 2003-09-30
PCT/US2004/031855 WO2005044807A2 (en) 2003-09-30 2004-09-29 Benzoimidazole compounds

Publications (2)

Publication Number Publication Date
JP2007508011A true JP2007508011A (ja) 2007-04-05
JP2007508011A5 JP2007508011A5 (enExample) 2007-11-22

Family

ID=38952593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534031A Pending JP2007508011A (ja) 2003-09-30 2004-09-29 ヒトヒンジコアミメティボディ、組成物、方法および用途

Country Status (21)

Country Link
US (10) US7432378B2 (enExample)
EP (1) EP1673348B1 (enExample)
JP (1) JP2007508011A (enExample)
KR (1) KR20060097024A (enExample)
CN (1) CN1886380B (enExample)
AR (1) AR045955A1 (enExample)
AT (1) ATE427303T1 (enExample)
AU (1) AU2004286933B2 (enExample)
BR (1) BRPI0414918A (enExample)
CA (1) CA2540704A1 (enExample)
DE (1) DE602004020364D1 (enExample)
ES (1) ES2323178T3 (enExample)
HR (1) HRP20060126A2 (enExample)
IL (1) IL174677A0 (enExample)
NO (1) NO20061950L (enExample)
NZ (1) NZ546259A (enExample)
PT (1) PT1673348E (enExample)
RU (1) RU2006110561A (enExample)
TW (1) TW200526637A (enExample)
WO (1) WO2005044807A2 (enExample)
ZA (1) ZA200603411B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501030A (ja) * 2009-08-05 2013-01-10 スパイダーバイオテック・エッセ・エッレ・エッレ 新規抗病原性ペプチド

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045955A1 (es) * 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos
JP5162236B2 (ja) 2004-03-25 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ イミダゾール化合物
CA2572218C (en) 2004-06-30 2013-06-11 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
CN101248051B (zh) 2005-05-26 2013-07-17 泰博特克药品有限公司 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法
AU2006264649A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
EP1954287B2 (en) † 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
EP1961745A1 (en) * 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
ATE478067T1 (de) 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
AU2007235577B2 (en) * 2006-03-31 2011-09-15 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor
WO2007120690A2 (en) * 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
FR2903311B1 (fr) * 2006-07-10 2012-06-15 Centre Nat Rech Scient Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
US8084466B2 (en) 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
UA100567C2 (ru) * 2008-06-12 2013-01-10 Янссен Фармацевтика Нв Использование антагонистов н4-гистаминовых рецепторов для лечения послеоперационных спаек
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EA020090B1 (ru) * 2008-06-30 2014-08-29 Янссен Фармацевтика Нв Способ получения и рекристаллизации кристаллического гемитартрата бензоимидазол-2-илпиримидинового производного
BRPI0919816A2 (pt) * 2008-09-26 2019-09-24 Eisai R&D Man Co Ltd uso compostos benzoxazólicos no tratamento de malária
US8354400B2 (en) 2008-09-26 2013-01-15 Eisai R&D Co., Ltd. Benzoxazole compounds and methods of use
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
EP2447263A1 (en) * 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
DE102011122420B4 (de) 2011-12-24 2016-07-28 Volkswagen Aktiengesellschaft Verfahren zur Feststellung der Spannungsfreiheit in einem elektrischen Hochvolt-System und ein elektrisches Hochvolt-System
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
EP2671870A1 (en) 2012-06-05 2013-12-11 Bioprojet Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
JO3516B1 (ar) 2013-03-06 2020-07-05 Janssen Pharmaceutica Nv مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
US11311013B2 (en) * 2018-05-22 2022-04-26 Nihon Nohyaku Co., Ltd. Benzimidazole compound or salt thereof, agricultural and horticultural insecticidal and acaricidal agent containing said compound, and method for using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US6184235B1 (en) * 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
TR200101239T2 (tr) 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
AR045955A1 (es) * 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6009030884, Ｐｒｏｔｅｉｎ ｅｘｐｒｅｓｓｉｏｎ ａｎｄ ｐｕｒｉｆｉｃａｔｉｏｎ． １９９８， Ｖｏｌ．１４， Ｎｏ．１， ｐ．１２０−１２４ *
JPN6009030885, Ｊｏｕｒｎａｌ ｏｆ ｎｅｕｒｏｓｃｉｅｎｃｅ ｒｅｓｅａｒｃｈ． ２００２ Ｊｕｎ １５， Ｖｏｌ．６８， Ｎｏ．６， ｐ．６５５−６６７ *
JPN6009030886, Ｃｅｌｌｕｌａｒ ａｎｄ ｍｏｌｅｃｕｌａｒ ｌｉｆｅ ｓｃｉｅｎｃｅｓ． １９９８， Ｖｏｌ．５４， Ｎｏ．５， ｐ．３９４−４０４ *
JPN6009030887, Ｎｅｐｈｒｏｌｏｇｙ， ｄｉａｌｙｓｉｓ， ｔｒａｎｓｐｌａｎｔａｔｉｏｎ． １９９９， Ｖｏｌ．１４， Ｓｕｐｐｌ．２， ｐ．８０−８４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501030A (ja) * 2009-08-05 2013-01-10 スパイダーバイオテック・エッセ・エッレ・エッレ 新規抗病原性ペプチド

Also Published As

Publication number Publication date
BRPI0414918A (pt) 2006-11-07
US20090270366A1 (en) 2009-10-29
US20050070550A1 (en) 2005-03-31
TW200526637A (en) 2005-08-16
US7723359B2 (en) 2010-05-25
NZ546259A (en) 2009-05-31
US7705143B2 (en) 2010-04-27
AR045955A1 (es) 2005-11-16
ZA200603411B (en) 2007-07-25
US20090270611A1 (en) 2009-10-29
US7662966B2 (en) 2010-02-16
EP1673348A2 (en) 2006-06-28
WO2005044807A3 (en) 2005-08-11
US20090275748A1 (en) 2009-11-05
HRP20060126A2 (en) 2008-05-31
AU2004286933A1 (en) 2005-05-19
ATE427303T1 (de) 2009-04-15
US20090264647A1 (en) 2009-10-22
IL174677A0 (en) 2006-08-20
US20090270613A1 (en) 2009-10-29
CN1886380A (zh) 2006-12-27
NO20061950L (no) 2006-06-29
US7723526B2 (en) 2010-05-25
CN1886380B (zh) 2010-12-22
US20090247508A1 (en) 2009-10-01
US20090264645A1 (en) 2009-10-22
CA2540704A1 (en) 2005-05-19
AU2004286933B2 (en) 2010-11-18
PT1673348E (pt) 2009-05-11
DE602004020364D1 (de) 2009-05-14
US20090281307A1 (en) 2009-11-12
US20090264646A1 (en) 2009-10-22
US7705149B2 (en) 2010-04-27
ES2323178T3 (es) 2009-07-08
EP1673348B1 (en) 2009-04-01
WO2005044807A2 (en) 2005-05-19
US7432378B2 (en) 2008-10-07
US7723527B2 (en) 2010-05-25
RU2006110561A (ru) 2007-10-10
KR20060097024A (ko) 2006-09-13

Similar Documents

Publication Publication Date Title
JP4810428B2 (ja) ヒトｅｐｏ模倣ヒンジコアミメティボディ、組成物、方法および使用
US7241733B2 (en) Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
US7718176B2 (en) Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
AU2003280130B2 (en) Mammalian CH1 deleted mimetibodies, compositions, methods and uses
EP1687452A2 (en) Human hinge core mimetibodies, compositions, methods and uses
US8071103B2 (en) Pharmaceutical composition comprising a human GLP-1 mimetibody
US20070135338A1 (en) Human GLP-1 mimetibodies, compositions, methods and uses
JP2006516084A (ja) Ｃｎｇｈ０００４ポリペプチド、抗体、組成物、方法および使用
US20120308573A1 (en) Anti-IL-23 Antibodies, Compositions, Methods and Uses
HK1138291A (en) Human epo mimentic hinge core mimetibodies, compositions, methods and uses
AU2011202563A1 (en) Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
MXPA06003677A (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071001

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110329